{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:10:58Z","timestamp":1783476658574,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.intimp.2022.109490","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T01:34:56Z","timestamp":1669772096000},"page":"109490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large\u2010scale pharmacovigilance analysis"],"prefix":"10.1016","volume":"114","author":[{"given":"Qian","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2022.109490_b0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/25785826.2020.1785654","article-title":"Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy","volume":"44","author":"Nakajima","year":"2021","journal-title":"Immunol. Med."},{"key":"10.1016\/j.intimp.2022.109490_b0010","doi-asserted-by":"crossref","unstructured":"J.R. Brahmer, C. Lacchetti, B.J. Schneider, M.B. Atkins, K.J. Brassil, J.M. Caterino, I. Chau, M.S. Ernstoff, J.M. Gardner, P. Ginex, S. Hallmeyer, J. Holter Chakrabarty, N.B. Leighl, J.S. Mammen, D.F. McDermott, A. Naing, L.J. Nastoupil, T. Phillips, L.D. Porter, I. Puzanov, C.A. Reichner, B.D. Santomasso, C. Seigel, A. Spira, M.E. Suarez-Almazor, Y. Wang, J.S. Weber, J.D. Wolchok, J.A. Thompson, N. National Comprehensive Cancer, Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, J. Clin. Oncol. 36(17) (2018) 1714-1768.","DOI":"10.1200\/JCO.2017.77.6385"},{"issue":"12","key":"10.1016\/j.intimp.2022.109490_b0015","first-page":"1721","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMAOncol"},{"issue":"5","key":"10.1016\/j.intimp.2022.109490_b0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic Complications of Immune Checkpoint Inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.intimp.2022.109490_b0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/asheducation.V2000.1.18.18","article-title":"New insights into the pathophysiology of acquired cytopenias","volume":"2000","author":"Young","year":"2000","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"5","key":"10.1016\/j.intimp.2022.109490_b0030","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2169\/internalmedicine.55.5436","article-title":"Coombs-negative autoimmune hemolytic anemia followed by anti-erythropoetin receptor antibody-associated pure red cell aplasia: a case report and review of literature","volume":"55","author":"Yoshimi","year":"2016","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109490_b0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bjh.17259","article-title":"Atezolizumab-induced pure red cell aplasia","volume":"193","author":"Bennett","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109490_b0040","article-title":"Durvalumab-Induced Secondary Pure Red Cell Aplasia Successfully Treated With Cyclosporin","volume":"1","author":"Watanabe","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2022.109490_b0045","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00262-008-0627-x","article-title":"Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma","volume":"58","author":"Gordon","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.intimp.2022.109490_b0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.14740\/jh507","article-title":"Bone Marrow Findings of Immune-Mediated Pure Red Cell Aplasia Following Anti-Programmed Cell Death Receptor-1 Therapy: A Report of Two Cases and Review of Literature","volume":"8","author":"Le Aye","year":"2019","journal-title":"J. Hematol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109490_b0055","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/CMR.0000000000000392","article-title":"A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma","volume":"27","author":"Yuki","year":"2017","journal-title":"Melanoma Res."},{"key":"10.1016\/j.intimp.2022.109490_b0060","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3389\/fonc.2020.01760","article-title":"Case Report: Successful Treatment of Steroid-Refractory Immune Checkpoint Inhibitor-Related Pure Red Cell Aplasia With Cyclosporin","volume":"10","author":"Gerard","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2022.109490_b0065","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ejca.2021.10.036","article-title":"Rare haematologic and neurologic drug reactions from immune checkpoint inhibition in a responding patient with metastatic anorectal mucosal melanoma","volume":"160","author":"Qaiyumi","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2022.109490_b0070","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.pathol.2020.01.391","article-title":"Pure red cell aplasia, immune thrombocytopenia and post-transfusion coombs\u2019 test negative haemolysis during anti-PD1 therapy for metastatic lung adenocarcinoma\u2013Case report","volume":"52","author":"Mahaliyana","year":"2020","journal-title":"Pathology"},{"issue":"16","key":"10.1016\/j.intimp.2022.109490_b0075","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2169\/internalmedicine.4467-20","article-title":"Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin","volume":"59","author":"Isoda","year":"2020","journal-title":"Intern. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109490_b0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/CMR.0000000000000724","article-title":"Unexpected pure red series aplastic anemia secondary to pembrolizumab treatment: a case report and literature review","volume":"31","author":"Meri-Abad","year":"2021","journal-title":"Melanoma Res."},{"issue":"11","key":"10.1016\/j.intimp.2022.109490_b0085","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMc1509362","article-title":"Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia","volume":"374","author":"Nair","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2022.109490_b0090","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1200\/OP.20.00047","article-title":"Refractory Autoimmune Hemolytic Anemia and Pure Red Cell Aplasia Secondary to Immunotherapy Requiring Prolonged Immunosuppression","volume":"16","author":"Hall","year":"2020","journal-title":"JCO Oncol. Pract."},{"issue":"5","key":"10.1016\/j.intimp.2022.109490_b0095","first-page":"264","article-title":"Successful Treatment of Nivolumab plus Ipilimumab-Mediated Pure Red-Cell Aplasia and Diabetes with Cyclosporine","volume":"11","author":"Padhi","year":"2021","journal-title":"J. Hematol. Oncol. Pharm."},{"issue":"1","key":"10.1016\/j.intimp.2022.109490_b0100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000380","article-title":"A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab","volume":"8","author":"Olson","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"18","key":"10.1016\/j.intimp.2022.109490_b0105","doi-asserted-by":"crossref","first-page":"6576","DOI":"10.1002\/cam4.3198","article-title":"Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data","volume":"9","author":"Chen","year":"2020","journal-title":"Cancer Med."},{"issue":"12","key":"10.1016\/j.intimp.2022.109490_b0110","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"J. The Lancet Oncology"},{"key":"10.1016\/j.intimp.2022.109490_b0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2022.109490_b0120","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/1759-7714.13281","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events","volume":"11","author":"Zhuang","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.intimp.2022.109490_b0125","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2022.07.001","article-title":"Somatic mutations in acquired pure red cell aplasia","author":"Kawakami","year":"2022","journal-title":"Seminars in Hematology, Elsevier"},{"issue":"1","key":"10.1016\/j.intimp.2022.109490_b0130","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109490_b0135","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.intimp.2022.109490_b0140","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjh.13376","article-title":"Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004\/2006 by the Japan PRCA collaborative study group","volume":"169","author":"Hirokawa","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109490_b0145","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the US Food and Drug Administration adverse event reporting system (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.intimp.2022.109490_b0150","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hon.2743","article-title":"Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019","volume":"38","author":"Ye","year":"2020","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.intimp.2022.109490_b0155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/TCRM.S193338","article-title":"Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients","volume":"15","author":"Zhou","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"issue":"4","key":"10.1016\/j.intimp.2022.109490_b0160","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2141.2008.07216.x","article-title":"Acquired pure red cell aplasia: updated review of treatment","volume":"142","author":"Sawada","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109490_b0165","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.autrev.2004.10.004","article-title":"Intravenous immunoglobulins in autoimmune-or parvovirus B19-mediated pure red-cell aplasia","volume":"4","author":"Mouthon","year":"2005","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2022.109490_b0170","doi-asserted-by":"crossref","unstructured":"O.J. van Not, R.J. Verheijden, A.J.M. van den Eertwegh, J.B.A.G. Haanen, M.J.B. Aarts, F.W.P.J. van den Berkmortel, C.U. Blank, M.J. Boers-Sonderen, J.-W.B. de Groot, G.A.P. Hospers, A.M. Kamphuis, E. Kapiteijn, A.M. May, M.M. de Meza, D. Piersma, R. van Rijn, M.A. Stevense-den Boer, A.A.M. van der Veldt, G. Vreugdenhil, W.A.M. Blokx, M.J.M. Wouters, K.P.M. Suijkerbuijk, Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma, JAMA Oncology (2022).","DOI":"10.1001\/jamaoncol.2022.5041"},{"key":"10.1016\/j.intimp.2022.109490_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103434","article-title":"Rechallenge of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"165","author":"Inno","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"10.1016\/j.intimp.2022.109490_b0180","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1093\/rheumatology\/keab249","article-title":"Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study","volume":"60","author":"Weill","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.intimp.2022.109490_b0185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J. Immunother. Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922009754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922009754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:51:17Z","timestamp":1761587477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922009754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":37,"alternative-id":["S1567576922009754"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109490","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large\u2010scale pharmacovigilance analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109490"}}